These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17392624)

  • 1. Dyslipidemia vs hyperglycemia.
    Feeman WE
    Prev Cardiol; 2007; 10(2):112. PubMed ID: 17392624
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipid management reduces cardiovascular complications in individuals with diabetes and prediabetes.
    Gosavi A; Flaker G; Gardner D
    Prev Cardiol; 2006; 9(2):102-7; quiz 108-9. PubMed ID: 16603829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atherogenic dyslipidemia in the cardiometabolic syndrome.
    Govindarajan G; Chowdhury N; Flaker G
    J Cardiometab Syndr; 2006; 1(2):153-5. PubMed ID: 17679818
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid disorders in type 2 diabetes.
    Laakso M
    Endocrinol Nutr; 2009 Dec; 56 Suppl 4():43-5. PubMed ID: 20629231
    [No Abstract]   [Full Text] [Related]  

  • 6. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials.
    Farmer JA
    Curr Atheroscler Rep; 2007 Aug; 9(2):162-8. PubMed ID: 17877926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of diet-induced dyslipidemia and hyperglycemia on mesenteric resistance artery structure and function in type 2 diabetes.
    Sachidanandam K; Hutchinson JR; Elgebaly MM; Mezzetti EM; Wang MH; Ergul A
    J Pharmacol Exp Ther; 2009 Jan; 328(1):123-30. PubMed ID: 18941121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular risk: diabetes.
    Collinson DJ; Rea R; Donnelly R
    Vasc Med; 2004 Nov; 9(4):307-10. PubMed ID: 15678624
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.
    Vavlukis M; Kedev S
    Curr Pharm Des; 2018; 24(4):427-441. PubMed ID: 29283060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triglycerides: how much credit do they deserve?
    Kohli P; Cannon CP
    Med Clin North Am; 2012 Jan; 96(1):39-55. PubMed ID: 22391250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: New insight into understanding the relation of type 2 diabetes mellitus, insulin resistance, and cardiovascular disease.
    Hsueh WA
    Am J Cardiol; 2003 Aug; 92(4A):1J-2J. PubMed ID: 12957320
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome.
    Robins SJ
    Curr Cardiol Rep; 2005 Nov; 7(6):457-64. PubMed ID: 16256016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diabetes and dyslipidemia: Why are they so closely related?].
    Rašlová K
    Vnitr Lek; 2016; 62(11):908-911. PubMed ID: 28128578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination lipid therapy in type 2 diabetes.
    Sacks FM; Carey VJ; Fruchart JC
    N Engl J Med; 2010 Aug; 363(7):692-4; author reply 694-5. PubMed ID: 20842772
    [No Abstract]   [Full Text] [Related]  

  • 15. Diabetes mellitus, insulin resistance, hyperglycemia, and stroke.
    Furie K; Inzucchi SE
    Curr Neurol Neurosci Rep; 2008 Jan; 8(1):12-9. PubMed ID: 18367034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The metabolic syndrome as a cluster of risk factors: is the whole greater than the sum of its parts?: comment on "The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis".
    Ding EL; Smit LA; Hu FB
    Arch Intern Med; 2010 Mar; 170(5):484-5. PubMed ID: 20212187
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing cardiovascular risk and managing dyslipidemia in women.
    Appel SJ; Floyd NA; Jones EJ
    Nurs Womens Health; 2007 Dec; 11(6):586-99. PubMed ID: 18088296
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of lipids and type 2 diabetes.
    Hermayer KL
    Curr Cardiol Rep; 2004 Nov; 6(6):443-50. PubMed ID: 15485606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between daily glucose fluctuation and coronary plaque properties in patients receiving adequate lipid-lowering therapy assessed by continuous glucose monitoring and optical coherence tomography.
    Kuroda M; Shinke T; Sakaguchi K; Otake H; Takaya T; Hirota Y; Osue T; Kinutani H; Konishi A; Takahashi H; Terashita D; Uzu K; Hirata K
    Cardiovasc Diabetol; 2015 Jun; 14():78. PubMed ID: 26062762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.